Third-line therapy for chronic myeloid leukemia: current status and future directions
Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion protein, formed by a translocation between chromosomes 9 and 22 that creates the Philadelphia chromosome. The BCR-ABL1 fusion protein is an optim...
Source: Journal of Hematology and Oncology - Category: Hematology Authors: Jorge Cortes and Fabian Lang Tags: Review Source Type: research
More News: Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Hematology | Leukemia | Translocation